Pfizer sweeps out a lineup of neuroscience drugs — as well as cancer and NASH programs — into the scrap heap
Anyone shopping for some early- and mid-stage neurosciences programs should look over the menu of discontinued programs out from Pfizer $PFE this morning.
As the pharma giant already noted, it is getting rid of everything on the neurosciences side except its late-stage pain program allied with Eli Lilly. So the chopping block today includes a Phase I gamma secretes approach, PF-06648671, as well as a GABA-A receptor agonist for epilepsy and a dopamine 1 activator for cognitive disorders.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.